Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongmei Sun

Showing results (221-230 of 229) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 229 results.
Advances in Therapy|September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III StudyYing Cheng, Zhanyu Pan, Lin Wu, et al.
Cancer Communications (London, England)|June 29, 2026
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III StudyLina Zhang, Jingxuan Wang, Tao Sun, et al.
Future Oncology (London, England)|June 3, 2026
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 studyZhiwei Chen, Fang Yang, Zhou Jiang, et al.
Lancet (London, England)|May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in ChinaShun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.
BMC Bioinformatics|September 20, 2008
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studiesLeming Shi, Wendell D Jones, Roderick V Jensen, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Nature Biotechnology|September 12, 2006
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements, Leming Shi, Laura H Reid, et al.
Pageof 23

Showing results (221-230 of 229) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 229 results.
Advances in Therapy|September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III StudyYing Cheng, Zhanyu Pan, Lin Wu, et al.
Cancer Communications (London, England)|June 29, 2026
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III StudyLina Zhang, Jingxuan Wang, Tao Sun, et al.
Future Oncology (London, England)|June 3, 2026
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 studyZhiwei Chen, Fang Yang, Zhou Jiang, et al.
Lancet (London, England)|May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in ChinaShun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.
BMC Bioinformatics|September 20, 2008
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studiesLeming Shi, Wendell D Jones, Roderick V Jensen, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Nature Biotechnology|September 12, 2006
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements, Leming Shi, Laura H Reid, et al.
Pageof 23